Optimized second-generation mRNA vaccine demonstrated improved protection against…
In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19 -- known as CVnCoV and developed by CureVac -- reported approximately 48 percent efficacy against symptomatic…